Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991.View on euronews ...

Eli Lilly (NYSE:LLY) recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over ...

Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in ...

The Danish company said Jorgensen is leaving by mutual agreement with the board, though he’ll continue as chief 'for a period ...